This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cannella, B. Articles by Raine, C. S. Search for Related Content PubMed PubMed Citation Articles by Cannella, B. Articles by Raine, C. S.

(American Journal of Pathology. 2000;157:933-943.)
© 2000 American Society for Investigative Pathology

Regular Articles

Insulin-Like Growth Factor-1 Fails to Enhance Central Nervous System Myelin Repair during Autoimmune Demyelination

Barbara Cannella^*, David Pitt^*, Elisabetta Capello and Cedric S. Raine^*§

From the Departments of Pathology (Neuropathology),^*
Neurology,
and Neuroscience,^§
Albert Einstein College of Medicine, Bronx, New York; and the Laboratorio di Neuropatologia,
University of Genova, Genoa, Italy

Previous studies have shown that insulin-like growth factor-1 (IGF-1) has beneficial effects, both clinically and histopathologically, on experimental autoimmune encephalomyelitis (EAE), although results vary depending on species and treatment regimen. The present study investigated whether IGF-1, delivered at different time points during the acute and chronic phases of adoptively transferred EAE in SJL mice, had the ability to affect or enhance myelin regeneration. Central nervous system tissue sampled at different stages of treatment was subjected to detailed neuropathological, immunocytochemical and molecular analysis. The results revealed some transient clinical amelioration and low level remyelination after IGF-1 administration during the acute phase of EAE. However, central nervous system tissue from acute phase treated animals sampled at chronic time points and from animals given IGF-1 during the chronic phase revealed no enhancing effect on remyelination in comparison to vehicle-treated controls. Examination of oligodendrocyte progenitor populations also revealed no differences between IGF-1- and vehicle-treated groups. At the cytokine level, the immunomodulatory molecules TGF-ß2 and TGF-ß3 displayed significant decreases that may have contributed to the transient nature of the effect of IGF-1 on EAE. Together with evidence from previous studies, it appears doubtful that IGF-1 is a good candidate for treatment in multiple sclerosis, for which EAE serves as a major model.

This article has been cited by other articles:

				V. C. Russo, P. D. Gluckman, E. L. Feldman, and G. A. Werther The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain Endocr. Rev., December 1, 2005; 26(7): 916 - 943. [Abstract] [Full Text] [PDF]

				J. L. Mason, S. Xuan, I. Dragatsis, A. Efstratiadis, and J. E. Goldman Insulin-Like Growth Factor (IGF) Signaling through Type 1 IGF Receptor Plays an Important Role in Remyelination J. Neurosci., August 20, 2003; 23(20): 7710 - 7718. [Abstract] [Full Text] [PDF]

				J. Imitola, E. Y. Snyder, and S. J. Khoury Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis Physiol Genomics, August 15, 2003; 14(3): 171 - 197. [Abstract] [Full Text] [PDF]

				J. Penderis, S. A. Shields, and R. J. M. Franklin Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system Brain, June 1, 2003; 126(6): 1382 - 1391. [Abstract] [Full Text] [PDF]